Kaul D, Ogra P L
Department of Pediatrics, Children's Hospital, University of Texas Medical Branch, Galveston 77555-0351, USA.
Dev Biol Stand. 1998;95:141-6.
Most human pathogens are acquired through mucosal portals of entry, and replicate in the mucosal tissues. Subsequently, the infecting agent may invade the blood stream and produce disease at distant systemic sites. However, a large number of pathogenic organisms are limited to development of disease only at the site of initial mucosal replication. Studies carried out with naturally acquired infections and mucosally delivered vaccines have provided strong evidence for the existence of a common mucosal immune system in the organized lymphoid follicles in respiratory and intestinal epithelium, and in the mucosa of genital tract, mammary glands, conjunctiva, upper airways, and the middle ear cavity. Mucosal application of live attenuated oral poliovaccine (OPV), rubella virus vaccine (RA 27/3), adenoviruses, influenza A virus, rotavirus, salmonella, and cholera vaccines have demonstrated consistent development of secretory IgA, serum antibody, and cellular immune responses. Mucosal immunization appears to result in preferential expression of several integrins and cell adhesion molecules associated with homing of lymphocytes to mucosal sites of immunization. Induction of mucosal immune responses often result in specific protection against reinfection challenge and against illness. Replicating agents introduced via the parenteral route also result in the development of mucosal responses and protection against systemic illness. Parenteral immunization with non-replicating agents often fails to induce specific mucosal responses. Such immunization, however, is quite effective in mounting high levels of serum antibody with development of protection against systemic illness. Parenteral vaccines, such as enhanced potency inactivated polio vaccine (eIPV), Haemophilus influenzae type B (HIB), hepatitis B virus (HBV), and other non-mucosal vaccines, have been highly effective in preventing systemic disease during subsequent exposure to natural infection. Recent evidence has shown that parenteral immunization can also be quite effective in inducing varying degrees of functional mucosal antibody responses as detected by ELISA and less frequently by neutralization. Systemic illnesses such as poliomyelitis and Haemophilus influenzae meningitis and community circulation of these agents has been eliminated or significantly limited in many parts of the world with the exclusive use of inactivated vaccines. Based on these observations, it is suggested that development of serum immunological responses are effective in the prevention of systemic disease regardless of the types of vaccines or route of their administration. However, induction of pathogen-specific antibody or cellular immunity at the mucosal sites is best elicited by mucosal application of the antigen.
大多数人类病原体是通过黏膜入口获得的,并在黏膜组织中复制。随后,感染因子可能侵入血流并在远处的全身部位引发疾病。然而,大量致病生物仅局限于在最初的黏膜复制部位引发疾病。对自然获得性感染和黏膜接种疫苗的研究有力地证明,在呼吸道和肠道上皮的有组织淋巴滤泡以及生殖道、乳腺、结膜、上呼吸道和中耳腔的黏膜中存在共同的黏膜免疫系统。口服减毒活脊髓灰质炎疫苗(OPV)、风疹病毒疫苗(RA 27/3)、腺病毒、甲型流感病毒、轮状病毒、沙门氏菌和霍乱疫苗的黏膜接种已证明可一致地产生分泌型IgA、血清抗体和细胞免疫反应。黏膜免疫似乎导致几种整合素和细胞黏附分子的优先表达,这些分子与淋巴细胞归巢至免疫接种的黏膜部位有关。黏膜免疫反应的诱导通常会产生针对再次感染攻击和疾病的特异性保护。通过非肠道途径引入的复制性制剂也会导致黏膜反应的产生以及对全身性疾病的保护。用非复制性制剂进行非肠道免疫通常无法诱导特异性黏膜反应。然而,这种免疫在产生高水平血清抗体并形成针对全身性疾病的保护方面相当有效。非肠道疫苗,如高效灭活脊髓灰质炎疫苗(eIPV)、B型流感嗜血杆菌(HIB)、乙型肝炎病毒(HBV)和其他非黏膜疫苗,在预防随后自然感染期间的全身性疾病方面非常有效。最近的证据表明,非肠道免疫在诱导不同程度的功能性黏膜抗体反应方面也可能相当有效,这可通过ELISA检测到,较少情况下可通过中和检测到。在世界许多地区,仅使用灭活疫苗已消除或显著限制了脊髓灰质炎和B型流感嗜血杆菌脑膜炎等全身性疾病以及这些病原体在社区中的传播。基于这些观察结果,有人认为血清免疫反应的产生在预防全身性疾病方面是有效的,无论疫苗类型或给药途径如何。然而,在黏膜部位诱导病原体特异性抗体或细胞免疫最好通过抗原的黏膜接种来实现。